Cardiovascular Systems Names Kevin J. Kenny Executive Vice President of Sales and Marketing

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) has named Kevin J. Kenny executive vice president of sales and marketing, a new position, effective today. Kenny will oversee all sales and marketing functions with the goal of building on the marketplace success CSI has achieved since its first-generation Diamondback 360° product was launched in late 2007.

“Kevin has extensive executive experience in sales and marketing, managing large commercial organizations and delivering results in both market growth and share,” said David L. Martin, president and chief executive officer for Cardiovascular Systems. “We’re excited to have him play a leading role in commercializing our new Stealth 360°TM Orbital PAD System and driving physician adoption of our technology as the front-line treatment for peripheral arterial disease. We have established scientific proof of our orbital PAD systems’ utility, and we are introducing an easy-to-use product with the Stealth 360°. Adding Kevin to our team at this stage will raise CSI to a new level of growth and leadership in the vascular intervention market.”

Kenny brings more than 20 years of leadership experience to CSI. Prior to CSI, he held several positions at Medtronic, most recently executive consultant-special projects for Medtronic Spine and Biologics, and prior to that, vice president of U.S. sales for that division, which is Medtronic’s second-largest division. Kenny joined the Spine and Biologics division in 2002 and held regional and national sales positions with increasing responsibilities. Earlier, Kenny served as vice president of U.S. sales for Bausch and Lomb, as well as various sales leadership roles with B.Braun/McGaw. Kenny received a bachelor’s degree in business administration from California State University in Sacramento.

Kenny added, “I look forward to leveraging my medical device industry experience to position CSI for accelerated growth. I am excited about CSI’s products, commitment to innovation and research, and growth prospects.”

About Cardiovascular Systems, Inc.Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360® and Diamondback Predator 360® Orbital PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 46,000 PAD procedures have been performed using the Diamondback 360° in leading institutions across the United States.

CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its Diamondback 360° System in treating coronary arteries. The coronary system is under clinical investigation and is currently not commercially available in the United States.

For more information, visit the company’s website at www.csi360.com.

Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024